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Systemic sclerosis is a connective tissue disease charac-
terized by excessive deposition of extracellular matrix
in the skin as well as various internal organs. Cellular
in¢ltrates are found in the dermis in early systemic
sclerosis, which are suggested to play an important part.
Recent studies suggest the involvement of monocyte
chemoattractant protein-1, a C-C chemokine, in the ¢-
brotic process. This study examines the role of mono-
cyte chemoattractant protein-1 in the induction of
dermal sclerosis in a murine model of bleomycin-
induced scleroderma. Immunohistochemical analysis
showed that expression of monocyte chemoattractant
protein-1 in the in¢ltrating mononuclear cells was en-
hanced at 2 to 3 wk following bleomycin treatment,
whereas expression of monocyte chemoattractant pro-
tein-1 in ¢broblasts was detected at later stages in the
sclerotic skin. Reverse transcriptase^polymerase chain re-
action analysis showed that monocyte chemoattractant
protein-1 mRNA expression in the lesional skin peaked
at 2 to 3 wk following bleomycin treatment. Expression
of CCR-2, a major receptor for monocyte chemo-
attractant protein-1, was also upregulated in the lesional
skin at both protein and mRNA levels following
bleomycin treatment. Administration of anti-monocyte
chemoattractant protein-1 neutralizing antibody to-
gether with local bleomycin treatment reduced dermal
sclerosis, along with a decrease of collagen content in
the skin as well as mRNA expression of type I collagen.
In vitro analysis showed that stimulation with monocyte
chemoattractant protein-1 (10 ng per mL) upregulated
a1(I) collagen and decorin mRNA expression in normal
dermal ¢broblasts, whereas mRNA levels of ¢bronectin
and biglycan were not altered. These data suggest that
monocyte chemoattractant protein-1 and CCR-2 sig-
naling plays an important part in the pathogenesis of
bleomycin-induced scleroderma. Monocyte chemoat-
tractant protein-1 may contribute to the induction of
dermal sclerosis via its direct e¡ect of upregulation
of mRNA expression of extracellular matrix on ¢bro-
blasts, as well as indirect e¡ect mediated by a number
of cytokines released from immunocytes recruited into
the lesional skin. Key words: animal model/bleomycin/CCR-
2/monocyte chemoattractant protein-1/scleroderma. J Invest
Dermatol 121:510 ^516, 2003
S
ystemic sclerosis (SSc) is an autoimmune disorder with
unknown etiology, characterized by excessive accumu-
lation of extracellular matrix in the involved skin or
various internal organs and vascular involvement (Krieg
and Meurer, 1988; LeRoy et al, 1991). Activated ¢bro-
blasts in the a¡ected areas produce high amounts of collagen
(Bostein et al, 1982; Krieg et al, 1986; Mauch et al, 1993). One of
the characteristic histologic features is the in£ammatory in¢ltrates
of mononuclear cells (Fagundus and LeRoy, 1994; Postlethwaite,
1995), which is associated with increased collagen synthesis in the
surrounding ¢broblasts (Fleischmajer et al, 1977; Schar¡etter et al,
1988). In£ammatory cells are potent candidates for releasing cyto-
kines, which play a crucial part in initiating and/or leading to
the sequential events of ¢brosis (LeRoy et al, 1989; Kovacs and
DiPietro, 1994).
Monocyte chemoattractant protein (MCP)-1 is a chemoattrac-
tant for monocytes and T cells, belonging to a C-C chemokine
superfamily of small proteins that are important in recruiting
and activating leukocytes during in£ammation (Rollins et al,
1988; Leonard and Yoshimura, 1990). MCP-1 has also been char-
acterized as the murine JE gene product. Previous studies have
shown that numerous types of cells, including ¢broblasts, en-
dothelial cells, epithelial cells, mononuclear cells, smooth muscle
cells, and mast cells are capable of expressing MCP-1 in the pre-
sence of serum or speci¢c stimuli (Leonard and Yoshimura, 1990;
Selvan et al, 1994). Recent studies have demonstrated that MCP-1
gene expression is upregulated in human idiopathic pulmonary
¢brosis (Antoniades et al, 1992), as well as rodent models of bleo-
mycin-induced pulmonary ¢brosis (Zhang et al, 1994) or crescent
nephritis and interstitial kidney ¢brosis (Lyoid et al, 1997). A re-
cent in vitro study shows that MCP-1 upregulates type I collagen
mRNA expression in rat lung ¢broblasts, which is indirectly
mediated by endogenous upregulation of transforming growth
factor (TGF)-b gene expression (Gharaee-Kermani et al, 1996).
We previously reported that MCP-1 enhances expression of ma-
trix metalloproteinase-1 and -2, as well as tissue inhibitor of me-
talloproteinase-1 in cultured skin ¢broblasts (Yamamoto et al,
2000a). In addition, MCP-1 expression was increased in scleroder-
ma ¢broblasts both in vitro (Yamamoto et al, 2001a) and in vivo
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(Hasegawa et al, 1999; Yamamoto et al, 2001b). These results sug-
gest an important involvement of MCP-1 in the pathogenesis of
scleroderma.
We have recently established a mouse model for scleroderma
by repeated application of bleomycin (Yamamoto et al, 1999a, b,
2000b, c; Yamamoto and Nishioka, 2002). Local injections of
bleomycin-induced dermal sclerosis which mimics human scler-
oderma both histologically and biochemically in several mice
strains. In this study, we examined the role of MCP-1 and its re-
ceptor, CCR-2, in the pathogenesis of bleomycin-induced dermal
sclerosis.
MATERIALS AND METHODS
Animals Speci¢c pathogen-free, female C3H/HeJ mice (6 wk old;
weighing about 20 g) were purchased from Japan Clea (Tokyo, Japan) and
maintained with food and water ad libitum. All mice were treated
humanly, and all the experiments were performed in accordance with
proper institutional approval.
Development of dermal sclerosis by bleomycin Bleomycin (Nippon
Kayaku Co. Ltd, Tokyo, Japan) was dissolved in phosphate-bu¡ered saline
(PBS) at a concentration of 1 mg per mL. One hundred microliters of
bleomycin or control PBS were injected into the shaved back of mice
every other day for 4 wk with a 26-gauge needle. In each group, six mice
were examined.
Immunohistochemical expression Biopsy was performed from the
shaved back skin on the next day of the ¢nal treatment. The skin pieces
were cut into two. One was ¢xed in 10% formalin solution and
embedded in para⁄n, and the other was snap-frozen in OCT compound
(Miles, Elkhart, Indiana) in liquid nitrogen and stored immediately at ^
801C. Five micrometer thick cryostat sections were prepared on poly L-
lysin coated slides. Immunohistochemistry was performed by the avidin^
biotin peroxidase technique using anti-murine MCP-1 antibody (Genzyme
Techne, Minneapolis, Minnesota) (diluted in PBS, 1:250) or anti-CKR-2B
antibody (Santa Cruz Biotechnology Inc., Santa Cruz, California) 1:250.
The sections were developed with 3,30 -diaminobenzidine solution as
chromogen. They were counterstained with hematoxylin, dehydrated,
cleared, and mounted. Negative controls were prepared by omission of
the primary antibody and by its substitution for corresponding IgG.
RNA isolation and reverse transcriptase^polymerase chain reac-
tion (reverse transcriptase^PCR) Total RNA was isolated from
biopsied skin tissues using RNeasy Mini Kit (Qiagen, Tokyo, Japan).
Complementary single-stranded DNA was synthesized from total RNA
by reverse transcription. Initially, 100 ng of total RNA in DEPC-treated
water was heated at 651C for 5 min and cooled rapidly. After adding 1 mL
of 10PCR bu¡er (500 mM KCl, 100 mM Tris^HCl bu¡er, pH 8.4, 15
mM MgCl2 and 0.01% gelatin), 1 mL of 25 mM aNTP (Takara, Tokyo,
Japan), 1 mL of 10aŁ  hexanucleotide mixture (Roche Diagnostics GmbH,
Mannheim, Germany), 20 U of ribonuclease inhibitor (Takara) and 3 U of
RAV-2 reverse transcriptase (Takara), the mixture was incubated at 421C
for 60 min, heated at 941C for 5 min and quick-chilled on ice. The
cDNA was ampli¢ed by PCR using Ready-to-Go PCR beads
(Amersham Pharmacia Biotech, Piscataway, New Jersey) with the speci¢c
primers for MCP-1 (sense; 50CTCACCTGCTGCTACTCATTC 30,
anti-sense; 50 GCATGAGGTGGTTGTGAAAAA 30), CCR-1 (sense; 50
GTGTTCATCATTGGAGTGGTGG 30, anti-sense 50 GGTTGAACAGGT-
AGATGCTGGTC 30), CCR-2 (sense; 50 TGTTACCTCAGTTCATCCA-
CGG 30, anti-sense; 50 CAGAATGGTAATGTGAGCAGGAAG 30), type I
collagen (sense; 50 TGGTGCCAAGGGTCTCACTGGC 30, anti-sense; 50
GGACCTTGTACACCACGTTCACC 30), and GAPDH (sense; 50 TGAA-
GGTCGGTGTGAACGGATTTGGC 30, anti-sense; 50 CATGTAGGCCA-
TGAGGTCCACCAC 30). Other primers for MIP-1a, MIP-1b, and
RANTES were purchased from Biosource International (Camarillo,
California). The PCR conditions for ampli¢cation were as follows; the
mixture was ¢rst incubated for 1 min and 30 s at 941C and then cycled 30
times at 941C for 25 s, 551C for 30 s, 721C for 45 s, followed by extension
at 721C for 10 min. For GAPDH, ampli¢cation was performed 25 cycles.
Cycle curve studies con¢rmed that ampli¢cation occurred in a linear range.
After ampli¢cation, PCR products were subjected to electrophoresis on
1.7% agarose gels and detected by ethidium bromide under ultraviolet
illuminator. For negative control, total cellular RNA without reverse
transcription was used.
Cell culture Primary human normal dermal ¢broblasts were established
by outgrowth from skin biopsies of healthy donors (n¼ 4, aged 40^65 y
old) after informed consent. Cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium supplemented with 10% heat inactivated fetal
bovine serum, 2 mM glutamine, 50 mg sodium ascorbate per mL, 100 U
per mL penicillin, 100 mg streptomycin per mL, and grown in the moist
atmosphere of a CO2 incubator at 371C. Cells were used at passage
numbers 3 to 6.
Stimulation by MCP-1 After the seeded ¢broblasts were grown
semicon£uent in the monolayer, the medium was changed to Dulbecco’s
modi¢ed Eagle’s medium without fetal bovine serum. Twenty-four hours
later, cells were incubated with 10 ng MCP-1 per mL (R&D Systems,
Minneapolis, Minnesota) for 6 to 24 h.
Northern blot analysis Total RNA was extracted from cultured
¢broblasts as described above. Aliquots of 5 mg per lane were
electrophoresed in denaturing agarose gels containing 0.66 M
formaldehyde, transferred to GeneScreen membranes (NEN Life Science
Products, Bostan, Massachusetts), ¢xed by ultraviolet cross-linking and
hybridized to cDNA probes speci¢c for a1(I) collagen (Hf 677) (Chu et al,
1982), ¢bronectin (FN 711) (Bernard et al, 1985), decorin (Krusius and
Ruoslahti, 1986), biglycan (Fisher et al, 1989), and GAPDH (Fort et al,
1985), which were labeled by random priming using [a-32P]deoxycytidine
triphosphate. Filters were hybridized overnight at 421C in 50%
formamide, 5aŁ  sodium citrate/chloride bu¡er, 100 mg denatured salmon
sperm DNA per mL, 5aŁ Denhardt’s, washed twice at room temperature
in 2aŁ  sodium citrate/chloride bu¡er, 0.1% sodium dodecyl sulfate,
followed by washing step at high stringency (62^651C in 0.1aŁ  sodium
citrate/chloride bu¡er, 0.1% sodium dodecyl sulfate). Autoradiography
was performed from 6 h to 1 d at ^801C using intensifying screens
(Kodak, Rochester, New York). Signal intensities were determined by
densitometry, and normalized to GAPDH.
Administration of anti-MCP-1 antibody To determine the e¡ect of
the antibody on the induction of dermal sclerosis, we intravenously admin-
istered anti-murine MCP-1 neutralizing antibody (Genzyme Techne)
250 mg per mL 30 min before subcutaneous injections of bleomycin
(1 mg per mL). Fifty microliters of anti-MCP-1 antibody was injected
from tail vein (n¼ 6) every other day for 4 wk and the back skins were
harvested. Normal goat serum (NGS) (n¼ 6) and anti-RANTES
neutralizing antibody (Genzyme Techne) 250 mg per mL (n¼ 6) were
used as a control under the same protocol.
Collagen content Collagen deposition was estimated by determining
the total collagen content of the 8 mm punch biopsy specimens using the
Sircol Collagen Assay kit (Biocolor, Northern Ireland) according to the
manufacturer’s instructions. The biopsies were homogenized in 0.5 M
acetic acid, and 1 mL of Sircol dye reagent that binds to collagen was
added to each sample and then mixed for 30 min. After centrifugation,
the pellet was suspended in 1 mL of the alkali reagent included in the kit
and assessed colorimetrically at 540 nm by a spectrophotometer. Collagen
standard solutions were utilized to construct a standard curve. Results were
expressed as a percentage compared with control group that received only
PBS injections.
Statistics Results were expressed as mean7SD. Signi¢cance testing was
analyzed using Mann^Whitney U test. po0.05 was considered to be
signi¢cant.
RESULTS
Expression of MCP-1 and CCR-2 in the lesional skin of
bleomycin-induced scleroderma To begin with, immuno-
histochemical detection of MCP-1 was examined in the lesional
skin. Fibroblasts and mononuclear cells were morpho-
logically identi¢ed by a few dermatologists in our department.
MCP-1-positive cells were weakly detected on scattered
mononuclear cells in PBS-treated skin (Fig 1A). Fibro-
blastic cells were negatively stained with MCP-1 in PBS-
treated skin. By contrast, MCP-1 was detectable on the
in¢ltrating mononuclear cells in the dermis at 1 wk, and the
number of MCP-1-positive cells peaked at 2 to 3 wk in
bleomycin-treated mice (Fig 1B). In addition, the positively
labeled ¢broblastic cells were also localized in the sclerotic
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dermis at later stages (Fig 1C). MCP-1 was also detected in
keratinocytes, endothelial cells, and possibly mast cells.
CCR-2 is the major receptor for MCP-1. MCP-1 and CCR-2
have been implicated in several in£ammatory diseases. In this
study, we examined the involvement of CCR-2 in the induction
of dermal sclerosis induced by bleomycin. Immunohistochemical
examination revealed that CCR-2 expression was enhanced on
the in¢ltrating mononuclear cells at 2 to 3 wk following bleo-
mycin treatment, as compared with PBS treatment (Fig 1D,E).
Thereafter, CCR-2 expression on the in¢ltrating mononuclear
cells was decreased. On the contrary, CCR-2 was also detected
on the ¢broblastic cells in the sclerotic dermis after 4 wk
(Fig 1F). This immunohistologic distribution demonstrated
concurrent upregulation of MCP-1 and CCR-2 with enhanced
expression on mononuclear cells at early in£ammatory stages
and on ¢broblasts at later sclerotic stages.
Results of reverse transcriptase^PCR analysis showed that
mRNA expression of MCP-1was increased and peaked at 2 to 3
wk following bleomycin treatment (Fig 2). The highest mRNA
expression of MCP-1 coincides with the kinetics followed by the
in¢ltrating leukocytes. In addition to MCP-1, mRNA expression
of MIP-1a and MIP-1b was also upregulated at 3 wk after
bleomycin treatment. On the other hand, RANTES mRNA
expression was not signi¢cantly altered during the course.
Results of reverse transcriptase^PCR analysis showed
increased expression of CCR-2 mRNA, which reached a
maximum at 2 to 3 wk following bleomycin treatment (Fig 3).
CCR-1 mRNA level was mildly upregulated at 2 wk following
bleomycin treatment.
Inhibition of dermal sclerosis by antibody against MCP-
1 Next, e¡ect of anti-MCP-1 neutralizing antibody was
examined to determine whether blockade of MCP-1 activity
suppresses the induction of dermal sclerosis. Mice treated with
bleomycin (1 mg per mL) and intravenous NGS showed de¢nite
dermal sclerosis with thickened collagen bundles and deposition
of homogeneous materials in the dermis (Fig 4A). On the
contrary, systemic administration of anti-MCP-1 antibody
together with local bleomycin treatment every other day for 4
wk suppressed the induction of dermal sclerosis (Fig 4A). The
number of in¢ltrating mononuclear cells was reduced up to
50% after anti-MCP-1 treatment. Dermal thickness was also
decreased after the treatment with anti-MCP-1 antibody.
mRNA expression of type I collagen showed a partial reduction
in mice treated with bleomycin and anti-MCP-1 antibody, as
Figure1. Immunohistologic detection of MCP-1 and CCR-2 in the lesional skin following treatment with either PBS (4 wk) or bleomycin
(BLM; 1^4 wk).MCP-1 expression was faint to absent in mononuclear cells in the PBS-treated skin (A). By contrast, MCP-1 expression is upregulated on
the in¢ltrating mononuclear cells in the lower dermis at 2 wk (B), and furthermore on ¢broblastic cells (arrowheads) in the sclerotic skin at 4 wk (C). CCR-2
expression was weakly detected in the PBS-treated skin (D), whereas increased on the in¢ltrating mononuclear cells (E) as well as on ¢broblastic cells
(arrowheads) (F) in the bleomycin-treated skin. Magni¢cation: (A,B,D,E) aŁ 200; (C,F) aŁ 400. Scale bar: (A,B,D,E) 50 mm; (C,F) 25 mm.
Figure 2. Reverse transcriptase^PCR analysis of MCP-1, MIP-1a,
MIP-1b, and RANTES.Total RNAwas isolated from skin samples trea-
ted with either PBS for 4 wk (Cont) or bleomycin (1^4 wk), and analyzed
with speci¢c primers. Results shown are representative of three indepen-
dent experiments.
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compared with that treated with bleomycin and NGS (Fig 4B).
Collagen content in the skin treated with bleomycin and NGS
(18178.1% of control) showed a signi¢cant decrease after the
treatment with bleomycin and anti-MCP-1 antibody (1501C
9.9% of control) (po0.05) (Fig 4C). On the contrary, treatment
with anti-RANTES antibody together with local bleomycin
injections did not reduce dermal sclerosis (not shown), and there
was no signi¢cant di¡erence in the collagen contents in the skin
between mice treated with bleomycin and NGS and those treated
with bleomycin and anti-RANTES antibody (17778.9% of
control) (Fig 4C).
MCP-1 enhances mRNA expression of a1(I) collagen in
cultured ¢broblasts Finally, we investigated the direct e¡ect
of MCP-1 on the induction of extracellular matrix in cultured
¢broblasts. The time course of a1(I) collagen, ¢bronectin,
decorin, and biglycan mRNA expression was examined by
northern blot analysis in normal dermal ¢broblasts exposed to
10 ng MCP-1 per mL for di¡erent time periods (6^24 h). As
shown in Fig 5, a1(I) collagen mRNAwas upregulated as early
as 6 h and further increased at 24 h. Densitometric quanti¢cation
revealed up to 4.3-fold increase of a1(I) collagen mRNA
expression by MCP-1. Decorin mRNA expression showed its
peak at 12 h, and waned to basal level at 24 h. MCP-1
upregulated a1(I) collagen and decorin mRNA expression in a
concentration-dependent manner ranging from 1 to 50 ng per
mL (data not shown). On the contrary, mRNA levels of
¢bronectin and biglycan were not signi¢cantly altered.
DISCUSSION
Recent studies suggest that MCP-1 is involved in ¢brotic process,
including human idiopathic pulmonary ¢brosis (Antoniades et al,
1992), acute hepatic ¢brogenesis (Marra et al, 1998), as well as ex-
perimental animal models of wound healing (DiPietro et al, 1995),
lung ¢brosis induced by bleomycin (Zhang et al, 1994), and renal
¢brosis (Lyoid et al, 1997).We have recently shown that MCP-1
expression is upregulated in scleroderma skin (Yamamoto et al,
2001b), as well as cultured scleroderma ¢broblasts (Yamamoto
et al, 2001a). Increased expression of MCP-1 in scleroderma has also
been reported by other groups (Distler et al, 2001; Galindo et al,
2001a). Here we demonstrate that MCP-1 expression is enhanced
in the lesional skin of an in vivomodel for scleroderma. Immuno-
histologic localization revealed that both mononuclear cells and
¢broblasts were the predominant cellular sources of MCP-1.
MCP-1 was detected on the in¢ltrating mononuclear cells at re-
latively early phases, and thereafter also detected on ¢broblasts in
the sclerotic stages. MCP-1 expression in ¢broblasts can play an
important part in the development of ¢brosis in scleroderma. It
has been shown to modulate connective tissue deposition by both
inducing collagen synthesis and collagenase production. MCP-1
Figure 4. E¡ect of anti-MCP-1 antibody on bleomycin-induced dermal sclerosis. (A) Anti-MCP-1 antibody blocks the induction of scleroderma
induced by bleomycin. Mice were treated with bleomycin (1 mg per mL) together with intravenous administration of either anti-MCP-1 antibody (n¼ 6)
or NGS (n¼ 6). Mice treated with bleomycin and NGS for 4 wk demonstrate de¢nite dermal sclerosis with thickened collagen bundles in the thickened
dermis (upper). Mice treated with bleomycin and anti-MCP-1 neutralizing antibody for 4 wk show reduction of dermal sclerosis (lower). Hematoxylin and
eosin stain, original magni¢cation aŁ 140. Scale bar: 100 mm. (B) Type I collagen mRNA expression. Total RNA was isolated from the lesional skin and
analyzed by reverse transcriptase^PCR. Lane 1: mice treated with bleomycin and NGS for 4 wk. Lane 2: anti-MCP-1 treated mice together with bleomycin
for 4 wk. Results shown are representative of three independent experiments. (C) Collagen content in the skin. Each value (% of control) was shown as
closed circles. Mean7SD are shown. Collagen content was signi¢cantly suppressed in mice treated with intravenous administration of anti-MCP-1 anti-
body together with local bleomycin, compared with those treated with NGS and bleomycin (po0.05).
Figure 3. Reverse transcriptase^PCR analysis of CCR-1 and CCR-
2.Total RNAwas isolated from skin samples treated with either PBS for 4
wk (Cont) or bleomycin (1^4 wk), and analyzed with speci¢c primers. Re-
sults shown are representative of three independent experiments.
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produced by activated ¢broblasts could act as a chemoattractant
for mononuclear cells, which contribute to the initial in£amma-
tory in¢ltrate localized around small blood vessels in the dermis
in the early stages of scleroderma and could be involved in the
perpetuation of the process. These in¢ltrating cells have been
shown to play a disease-triggering role releasing a number of
growth factors, cytokines, and chemokines, many of which are
known to activate matrix production, ¢broblast proliferation,
and migration.
We previously reported that mast cells are increased in number
in the lesional skin in parallel with the induction of dermal
sclerosis by bleomycin (Yamamoto et al, 1999a). In particular,
marked degranulation is prominent at an early phase. Mast cells
are suggested as important initiators of SSc (Gruber, 1995), as
mast cells produce a number of cytokines, growth factors, and
mediators that are capable of activating ¢broblasts or endothelial
cells (Galli, 1989). MCP-1 is shown to be abundantly expressed on
mast cells (Selvan et al, 1994; Yamamoto et al, 2001d). We and
others previously showed that stem cell factor upregulates MCP-
1 gene expression in human mast cells (Baghestanian et al, 1997;
Yamamoto et al, 2001d).We speculated that mutual interaction of
stem cell factor released from ¢broblasts and MCP-1 from mast
cells may play an important part in ¢brosis (Yamamoto et al,
2001d). Also, previous studies demonstrated that MCP-1 can in-
duce degranulation of mast cells (Conti et al, 1995). Taken to-
gether, MCP-1 released from mononuclear cells, mast cells, and
¢broblasts are supposed to play an important part in the induc-
tion of cutaneous sclerosis in this model.
Recently, excessive oxidative stress has been implicated in the
pathogenesis of scleroderma (Bruckdorfer et al, 1995; Stein et al,
1996; Casciola-Rosen et al, 1997; Sambo et al, 1999). Bleomycin is
known to generate reactive oxygen species, such as superoxide
and hydroxyl radicals. Reactive oxygen species can cause several
abnormalities such as endothelial cell damage or enhanced plate-
let activation, leading to upregulation of the expression of adhe-
sion molecules or secretion of in£ammatory or ¢brogenic
cytokines, including platelet-derived growth factor and TGF-b.
Other e¡ects of oxygen radicals include the stimulation of skin
¢broblast proliferation at low concentrations (Murrell et al, 1990),
and the production of increased amounts of collagen (Chojkier
et al, 1989). A recent study has demonstrated that constitutive
production of reactive oxygen species by scleroderma ¢broblasts
is essential to ¢broblast proliferation and expression of type I
collagen gene (Sambo et al, 2001). We previously reported the
inhibitory e¡ect of lecithinized superoxide dismutase on bleomy-
cin-induced scleroderma (Yamamoto et al, 1999c). On the other
hand, it is also reported that oxidative stress transiently induces
MCP-1 mRNA and protein expression in cultured dermal
¢broblasts (Galindo et al, 2001b). Therefore, elevated levels of
MCP-1 in this model might be induced, in part, via reactive
oxygen species by bleomycin.
Current studies suggest that an imbalance exists between the
type 1 and type 2 cytokine response in the pathogenesis of scler-
oderma. IL-4, which is produced by activated memoryTcells and
mast cells, is known to promote ¢broblast proliferation, collagen
gene expression, and collagen synthesis (Gillery et al, 1992; Post-
lethwaite et al, 1992; Sempowski et al, 1994). A recent report sug-
gests that most CD4þ T cell clones generated from scleroderma
skin biopsies exhibited type 2 cytokine pro¢les (Mavilia et al,
1997). In addition, serum in the majority of SSc patients showed
elevated levels of CD30 (Mavilia et al, 1997). MCP-1 is a crucial
factor for the development of type 2 responses. MCP-1 has been
shown to induce the expression of IL-4 (Hogaboam et al, 1999;
Gu et al, 2000; Trautman et al, 2000). Thus, increased levels of
MCP-1 are supposed to shift the type 2 polarization, which may
favor the imbalance in SSc. On the other hand, several studies
have demonstrated that type 2 cytokines induce MCP-1 from
multiple structural cell populations (Rollins and Pober, 1991;
Goebeler et al, 1997). Therefore, enhanced expression of MCP-1
may be induced, in part, by type 2 cytokines, which are supposed
to play a part in the induction of sclerotic skin. Such mutual in-
teraction may play a signi¢cant part in the induction of scleroder-
ma both at initial and later phases.
In this study, mRNA levels of MIP-1a and MIP-1bwere also
upregulated at 3 wk after bleomycin treatment, in addition to
MCP-1. MIP-1 are secreted by activated T cells, B cells mono-
cytes, and mast cells. MIP-1a is also reported to be highly ex-
pressed during many stages of interstitial ¢brotic diseases
(Hogaboam et al, 1998). MIP-1awas shown to play a part in the
recruitment of mononuclear and polymorphonuclear cells to the
lung in the bleomycin-induced pulmonary ¢brosis model (Smith
et al, 1994). These results suggest that MIP-1 may also be a key
molecule in macrophage tra⁄cking into in£ammatory area.
Chemokine responses are mediated by the interaction of the
soluble chemokine proteins with receptors. CCR-2 is the major
MCP-1 receptor, and MCP-1 binds to CCR-2 with high a⁄nity.
CCR-2 belongs to the family of G protein-coupled receptors.
Two isoforms with alternatively spliced intracellular carboxyl
tails, CCR2A and CCR2B, were isolated; however, they di¡er
only in their cytoplasmic carboxyl tails. CCR-2 is expressed
on monocytes, activated T cells, B cells, natural killer cells,
¢broblasts, and mast cells (Kunkel et al, 1993; Frade et al, 1997;
Hogaboam et al, 1999). Our results also show that bleomycin-induced
CCR-2 expression in the lesional skin in association with aug-
mented levels of MCP-1. Upregulation of CCR-2 in ¢broblasts
in parallel with the induction of dermal sclerosis may enhance the
susceptibility of the MCP-1 e¡ect. Thus, activation of CCR-2
was suggested to exert profound e¡ects on the ¢brotic process.
The inhibition of MCP-1 partially attenuated dermal sclero-
sis induced by bleomycin, when anti-MCP-1 antibody was
Figure 5. E¡ect of MCP-1 on a1(I) collagen, ¢bronectin, decorin,
and biglycan mRNA expression in human skin ¢broblasts. Semicon-
£uent cultures of normal dermal ¢broblasts were incubated for various
time periods (6^24 h) in the presence of 10 ng per mL MCP-1 in serum-
free medium. Total RNA (5 mg per lane) was analyzed by northern blot
hybridization with cDNA probes, as described in Materials and Methods. As
a control, RNA from a parallel culture (unstimulated), which was main-
tained for 24 h without MCP-1, was loaded. Results shown are representa-
tive of three independent experiments.
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administered throughout all stages. Blocking the activity of
MCP-1 led to the reduction of collagen production, resulted in
the suppression of dermal sclerosis in this model. On the con-
trary, administration of anti-RANTES antibody reduced neither
histologic dermal sclerosis nor collagen content in the skin. There
was a reduction in the number of skin monocytes/macrophages
up to nearly 50%, although we examined only one time point
at 4 wk. As mononuclear cells accumulation was not completely
inhibited by MCP-1 neutralization, other chemokines may con-
tribute to migration of mononuclear cells in this model. Mono-
nuclear cells are considered to be a major TGF-b producing cells.
MCP-1 can stimulate the production of TGF-b1 (Hogaboam
et al, 1999), which is a key cytokine in ¢brosis. It was reported
that inhibition of MCP-1 reduced TGF-b and procollagen
synthesis, thus improving renal ¢brosis in an animal model
(Lyoid et al, 1997). Therefore, amelioration of dermal sclerosis
by neutralizing MCP-1 activity may also be mediated through
reduction of TGF-b.
In vitro analysis showed that MCP-1 upregulates the mRNA
levels of a1(I) collagen and decorin in normal skin ¢broblasts,
whereas those of ¢bronectin and biglycan were not signi¢cantly
altered. Biglycan/PG-I and decorin/PG-II are two small proteo-
glycans with a core protein of similar size (42 kDa), containing
most often two and one chondroitin/dermatan sulfate glycosami-
noglycan side chains, respectively. Although these molecules dis-
play a high degree of structural similarities, our results showed
di¡erential regulation of these molecules by MCP-1. These data
indicate the direct e¡ect of MCP-1 to produce high amounts of
extracellular matrix (collagen and decorin) on ¢broblasts.
In conclusion, enhanced expression of MCP-1 and its corre-
sponding receptor, CCR-2, on both in¢ltrating mononuclear
cells and ¢broblasts suggest an important involvement of these
molecules in the pathogenesis of experimental scleroderma in-
duced by bleomycin. MCP-1 may play an important part in the
¢brotic process not only via indirect e¡ect through in£ammatory
cytokines derived from mononuclear cells recruited into the le-
sional skin, and activation and production of matrix metallopro-
teinases, as well as via direct e¡ect of upregulation of type I
collagen gene expression. Modulation of MCP-1/CCR-2 signal-
ing may implicate the therapeutic approach of experimental
scleroderma.
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